Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Glenmark Pharmaceuticals Launches GLIPIQ (Semaglutide) In India. Setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs. 325".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for the treatment of Type 2 Diabetes Mellitus, following approval from the Central Drugs Standard Control Organization (CDSCO) based on a Phase III clinical study conducted in India. The product is priced at Rs. 325 to Rs. 440 per week, significantly lowering the cost barrier for GLP-1 therapy in the country. GLIPIQ is available in both vial and pre-filled pen formats in three strengths (2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL), offering flexibility for patients and doctors. The company has also introduced 'Sankalp', a patient support program aimed at helping patients start and stay on the therapy. This launch builds on Glenmark's existing presence in the GLP-1 category through its Lirafit (Liraglutide) brand.
The affordable pricing and CDSCO-backed launch position Glenmark to capture meaningful share in India's growing diabetes and GLP-1 market, potentially boosting domestic formulation revenues, though competitive pricing may pressure margins in the segment.